128 related articles for article (PubMed ID: 24060976)
1. Characterization of a novel fusion protein from IpaB and IpaD of Shigella spp. and its potential as a pan-Shigella vaccine.
Martinez-Becerra FJ; Chen X; Dickenson NE; Choudhari SP; Harrison K; Clements JD; Picking WD; Van De Verg LL; Walker RI; Picking WL
Infect Immun; 2013 Dec; 81(12):4470-7. PubMed ID: 24060976
[TBL] [Abstract][Full Text] [Related]
2. A Novel
Ndungo E; Randall A; Hazen TH; Kania DA; Trappl-Kimmons K; Liang X; Barry EM; Kotloff KL; Chakraborty S; Mani S; Rasko DA; Pasetti MF
mSphere; 2018 Aug; 3(4):. PubMed ID: 30068560
[No Abstract] [Full Text] [Related]
3. Structural Insights of
Ferrari ML; Charova SN; Sansonetti PJ; Mylonas E; Gazi AD
Front Cell Infect Microbiol; 2021; 11():673122. PubMed ID: 33996640
[TBL] [Abstract][Full Text] [Related]
4. Vaccination with a Protective Ipa Protein-Containing Nanoemulsion Differentially Alters the Transcriptomic Profiles of Young and Elderly Mice following
Lu T; Raju M; Howlader DR; Dietz ZK; Whittier SK; Varisco DJ; Ernst RK; Coghill LM; Picking WD; Picking WL
Vaccines (Basel); 2024 Jun; 12(6):. PubMed ID: 38932347
[No Abstract] [Full Text] [Related]
5. Formulation and immunogenicity studies of type III secretion system needle antigens as vaccine candidates.
Barrett BS; Markham AP; Esfandiary R; Picking WL; Picking WD; Joshi SB; Middaugh CR
J Pharm Sci; 2010 Nov; 99(11):4488-96. PubMed ID: 20845448
[TBL] [Abstract][Full Text] [Related]
6. B memory cell responses to LPS, IVP and IpaB antigen after oral vaccination with Shigella sonnei vaccine candidates WRSs2 and WRSs3.
Venkatesan MM; Barnoy S; Frenck R; McNeal M; Baqar S
PLoS One; 2024; 19(1):e0290987. PubMed ID: 38232106
[TBL] [Abstract][Full Text] [Related]
7. Safety and colonization of two novel VirG(IcsA)-based live Shigella sonnei vaccine strains in rhesus macaques (Macaca mulatta).
Collins TA; Barnoy S; Baqar S; Ranallo RT; Nemelka KW; Venkatesan MM
Comp Med; 2008 Feb; 58(1):88-94. PubMed ID: 19793462
[TBL] [Abstract][Full Text] [Related]
8. Intradermal delivery of Shigella IpaB and IpaD type III secretion proteins: kinetics of cell recruitment and antigen uptake, mucosal and systemic immunity, and protection across serotypes.
Heine SJ; Diaz-McNair J; Andar AU; Drachenberg CB; van de Verg L; Walker R; Picking WL; Pasetti MF
J Immunol; 2014 Feb; 192(4):1630-40. PubMed ID: 24453241
[TBL] [Abstract][Full Text] [Related]
9. Impact of detergent on biophysical properties and immune response of the IpaDB fusion protein, a candidate subunit vaccine against Shigella species.
Chen X; Choudhari SP; Martinez-Becerra FJ; Kim JH; Dickenson NE; Toth RT; Joshi SB; Greenwood JC; Clements JD; Picking WD; Middaugh CR; Picking WL
Infect Immun; 2015 Jan; 83(1):292-9. PubMed ID: 25368115
[TBL] [Abstract][Full Text] [Related]
10. Development and preclinical evaluation of a trivalent, formalin-inactivated Shigella whole-cell vaccine.
Kaminski RW; Wu M; Turbyfill KR; Clarkson K; Tai B; Bourgeois AL; Van De Verg LL; Walker RI; Oaks EV
Clin Vaccine Immunol; 2014 Mar; 21(3):366-82. PubMed ID: 24403527
[TBL] [Abstract][Full Text] [Related]
11. The immune response of two microbial antigens delivered intradermally, sublingually, or the combination thereof.
Lee S; Picking WL; Tzipori S
Microbes Infect; 2014 Sep; 16(9):796-803. PubMed ID: 25111827
[TBL] [Abstract][Full Text] [Related]
12. Influence of oligomerization state on the structural properties of invasion plasmid antigen B from Shigella flexneri in the presence and absence of phospholipid membranes.
Adam PR; Dickenson NE; Greenwood JC; Picking WL; Picking WD
Proteins; 2014 Nov; 82(11):3013-22. PubMed ID: 25103195
[TBL] [Abstract][Full Text] [Related]
13. Biophysical characterization of the type III secretion tip proteins and the tip proteins attached to bacterium-like particles.
Choudhari SP; Chen X; Kim JH; Van Roosmalen ML; Greenwood JC; Joshi SB; Picking WD; Leenhouts K; Middaugh CR; Picking WL
J Pharm Sci; 2015 Feb; 104(2):424-32. PubMed ID: 24916512
[TBL] [Abstract][Full Text] [Related]
14.
Lu T; Das S; Howlader DR; Picking WD; Picking WL
Int J Mol Sci; 2024 Apr; 25(8):. PubMed ID: 38673913
[TBL] [Abstract][Full Text] [Related]
15. A broadly immunogenic polyvalent
Li S; Anvari S; Ptacek G; Upadhyay I; Kaminski RW; Sack DA; Zhang W
Infect Immun; 2023 Nov; 91(11):e0031623. PubMed ID: 37795982
[TBL] [Abstract][Full Text] [Related]
16. Impact of the TLR4 agonist BECC438 on a novel vaccine formulation against
Lu T; Das S; Howlader DR; Jain A; Hu G; Dietz ZK; Zheng Q; Ratnakaram SSK; Whittier SK; Varisco DJ; Ernst RK; Picking WD; Picking WL
Front Immunol; 2023; 14():1194912. PubMed ID: 37744341
[TBL] [Abstract][Full Text] [Related]
17. Toward a
Raso MM; Arato V; Gasperini G; Micoli F
Int J Mol Sci; 2023 Feb; 24(5):. PubMed ID: 36902092
[TBL] [Abstract][Full Text] [Related]
18. Facile synthesis of multi-faceted, biomimetic and cross-protective nanoparticle-based vaccines for drug-resistant Shigella: a flexible platform technology.
Baruah N; Ahamad N; Halder P; Koley H; Katti DS
J Nanobiotechnology; 2023 Jan; 21(1):34. PubMed ID: 36710326
[TBL] [Abstract][Full Text] [Related]
19. Systems approach to define humoral correlates of immunity to Shigella.
Bernshtein B; Ndungo E; Cizmeci D; Xu P; Kováč P; Kelly M; Islam D; Ryan ET; Kotloff KL; Pasetti MF; Alter G
Cell Rep; 2022 Aug; 40(7):111216. PubMed ID: 35977496
[TBL] [Abstract][Full Text] [Related]
20.
; ; . PubMed ID:
[No Abstract] [Full Text] [Related]
[Next] [New Search]
